P4‐050: Dysregulation of brain ApoE and cholesterol metabolism in APP transgenic mice
Helen K. Warwick(Princeton University), David Riddell(Eli Lilly (United States)), Jan Jacobsen(Princeton University), Julius J. Jefferson(Princeton University), Kevin Atchison(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter H. Reinhart(University of Massachusetts Amherst), Yolanda Kirksey(Princeton University), Hua Zhou(United Silicon Carbide (United States)), Menelas N. Pangalos(AstraZeneca (United Kingdom)), Suzan Aschmies(Princeton University), Cathleen Gonzales
Cited by 2
Related Papers
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
|Nature Medicine|2020|445
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
|Journal of Neuroscience|2008|351
Compartmentalization of β-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts
|Current Biology|2001|302